CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle

Vaccine

Volumn 27, Issue 14, 2009, Pages 2048-2054

  Kovacs Nolan, J ^a   Mapletoft, J W ^a   Latimer, L ^a   Babiuk, L A ^b   Hurk, S van Drunen Littel van den ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adjuvant; CpG ODN; Duration of immunity; Host defense peptide; Immune responses; Polyphosphazene

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE PLUS HEN EGG LYSOZYME PLUS INDOLICIDIN PLUS POLY(DI 4 DICARBOXYLATOPHENOXY)PHOSPHAZENE; GAMMA INTERFERON; INDOLICIDIN; LYSOZYME; POLY(DI 4 DICARBOXYLATOPHENOXY)PHOSPHAZENE; POLYMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CATTLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY SPECIFICITY; ANTIMICROBIAL CATIONIC PEPTIDES; CATTLE; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MURAMIDASE; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES;

EID: 61549132606     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.117     Document Type: Article

References (43)

1. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., and Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364 (2008) 272-280
2. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 19 6 (2002) 715-728
3. O'Hagan D.T., MacKichan M.L., and Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18 3 (2001) 69-85
4. Huang D.B., Wu J.J., and Tyring S.K. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect 49 3 (2004) 179-209
5. Paschine A., Ulmer J.B., and Valiante N.M. Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants. In: Schijns V.E.J.C., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, New York 58-72
6. Hauguel T.M., and Hackett C.J. Rationally-designed vaccine adjuvants: separating efficacy from toxicity. Front Biosci 13 (2008) 2806-2813
7. Kwissa M., Kasturi S.P., and Pulendran B. The science of adjuvants. Expert Rev Vaccines 6 5 (2007) 673-684
8. Singh M., and O'Hagan D.T. Recent advances in veterinary vaccine adjuvants. Int J Parasitol 33 5-6 (2003) 469-478
9. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 1 (1999) 19-25
10. McCluskie M.J., and Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 311 (2006) 155-178
11. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32 3 (1998) 155-172
12. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21 1-2 (2002) 127-137
13. Willson P.J., Rossi-Campos A., and Potter A.A. Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Can J Vet Res 59 4 (1995) 299-305
14. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 4 (2004) 249-258
15. Selsted M.E., Novotny M.J., Morris W.L., Tang Y.Q., Smith W., and Cullor J.S. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 267 7 (1992) 4292-4295
16. Andrianov A., Sargent J.R., Sule S.S., Le Golvan M.P., Woods A.L., Jenkins S.A., et al. Synthesis, physico-chemical properties and immunoadjuvant activity of water-soluble phosphazene polyacids. J Bioactive Compatible Polym 13 (1998) 243-256
17. Chaubal M.V., Gupta A.S., Lopina S.T., and Bruley D.F. Polyphosphates and other phosphorus-containing polymers for drug delivery applications. Crit Rev Ther Drug Carrier Syst 20 4 (2003) 295-315
18. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16 1 (1998) 92-98
19. Payne L.G., Van Nest G., Barchfeld G.L., Siber G.R., Gupta R.K., and Jenkins S.A. PCPP as a parenteral adjuvant for diverse antigens. Dev Biol Stand 92 (1998) 79-87
20. Wu J.Y., Wade W.F., and Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69 12 (2001) 7695-7702
21. Mutwiri G., Benjamin P., Soita H., and Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26 22 (2008) 2680-2688
22. Andrianov A.K., Marin A., and Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6 3 (2005) 1375-1379
23. Payne L.G., and Andrianov A.K. Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31 3 (1998) 185-196
24. Andrianov A.K., Svirkin Y.Y., and Le Golvan M.P. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5 5 (2004) 1999-2006
25. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 26 (2006) 5461-5472
26. Baca-Estrada M.E., Godson D.L., Hughes H.P., Van Donkersgoed J., Van Kessel A., Harland R., et al. Effect of recombinant bovine interleukin-1 beta on viral/bacterial pneumonia in cattle. J Interferon Cytokine Res 15 5 (1995) 431-439
27. Hughes H.P., Rossow S., Campos M., Rossi-Campos A., Janssen S., Godson D.L., et al. A slow release formulation for recombinant bovine interferon alpha I-1. Antiviral Res 23 1 (1994) 33-44
28. Ellis J.A., Godson D., Campos M., Sileghem M., and Babiuk L.A. Capture immunoassay for ruminant tumor necrosis factor-alpha: comparison with bioassay. Vet Immunol Immunopathol 35 3-4 (1993) 289-300
29. Schijns V.E.J.C. Unraveling "the immunologist's dirty little secret. In: Schijns V.E.J.C., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, New York 1-16
30. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 26 (2006) 5452-5460
31. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76 18 (2002) 9002-9010
32. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 89 Pt 1 (2008) 250-260
33. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22 2728 (2004) 3658-3668
34. Medzhitov R., and Janeway Jr. C.A. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9 1 (1997) 4-9
35. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 4 (2001) 461-470
36. Sinigaglia F., D'Ambrosio D., and Rogge L. Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol 23 7-8 (1999) 657-663
37. Xing Z., Zganiacz A., and Santosuosso M. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction. J Leukoc Biol 68 6 (2000) 897-902
38. Zganiacz A., Santosuosso M., Wang J., Yang T., Chen L., Anzulovic M., et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 113 3 (2004) 401-413
39. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93 7 (1996) 2879-2883
40. Wenner C.A., Guler M.L., Macatonia S.E., O'Garra A., and Murphy K.M. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 156 4 (1996) 1442-1447
41. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., and Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 61 1 (1985) 143-151
42. Garcon N., Van Mechelen M., and Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt. In: Schijns V.E.J.C., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, New York 161-177
43. O'Hagan D.T. Microparticles as vaccine delivery systems. In: Schijns V.E.J.C., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, New York 124-147